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1720 Abstracts December 2013carotid artery stenosis, and abdominal aortic aneurysm was 3.7%, 3.9%, and
0.9%, respectively. Prevalence of vascular disease increased with age (40-50
years: 2%, 51-60 years: 3.5%, 61-70 years: 7.1%, 71-80 years: 13.0%, 81-90
years: 22.3%, 91-100 years: 32.5%; P < .0001). The prevalence of vascular
disease in each vascular territory also increased with age. After adjustment
for sex, race-ethnicity, body mass index, family history of cardiovascular
disease, smoking, diabetes, hypertension, hypercholesterolemia, and exer-
cise, the odds of PAD (odds ratio [OR], 2.14; 95% conﬁdence interval
[CI], 2.12-2.15), carotid artery stenosis (OR, 1.8; 95% CI, 1.79-1.81),
and abdominal aortic aneurysm (OR, 2.33; 95% CI, 2.30-2.36) increased
with each decade of life.
Comment: Age is a well-known risk factor for atherosclerosis. The
data here, if anything, are likely to underestimate the prevalence of vascular
disease. Patients who present for screening studies, the so-called worried
well, may be more health oriented and live healthier lifestyles than those
who do not. After all, patients known to have vascular disease are not really
candidates for “screening” studies and, theoretically, would not be included
in the database. It seems they would be unlikely to pay for an examination to
conﬁrm what they already know.
Fistula First Is Not Always the Best Strategy for the Elderly
DeSilva RN, Patibandla BK, Vin Y, et al. J Am Soc Nephrol 2013;24:
1297-304.
Conclusions: Fistula ﬁrst is not clearly superior to graft ﬁrst in very
elderly patients. Each strategy is associated with similar mortality outcomes
in octogenarians and nonagenarians.
Summary: In patients requiring hemodialysis, one-third of ﬁstulas
fail to mature (Allon M et al, Kidney Int 2002;62:1109-24). In addition,
patients aged >65 years have twice the failure rate of younger patients
(Lok CE et al, J Am Soc Nephrol 2006;17:3204-12). A higher rate of
ﬁstulas that fail to mature may contribute to greater use of catheters.
Indeed, from the mid-1990s until recently, incident use of arteriovenous
(AV) grafts in elderly patients decreased from 28.2% to 4.2%, but at the
same time, incident catheter use increased from 56.8% to 82.3% (DeSilva
RN et al, Hemodial Int 2012;16:233-41; and Lacson E Jr et al, Am J
Kidney Dis 2009;54:912-21). Along with this, it is noted that the incident
hemodialysis population is aging, with an annual increase of 8% to 16% in
patients aged >75 years. In this paper, the authors sought to determine
mortality rates in the elderly population according to the initial type of
vascular access placed rather than the access used at initiation of hemodi-
alysis. The speciﬁc question was whether ﬁstula ﬁrst, as an intention-to-
treat strategy might not be the clearly superior predialysis vascular access
placement strategy in octogenarians. The paper analyzed data from
a cohort of 115,425 incident hemodialysis patients who were aged $65
years. Data were derived from the US Renal Data System with linked
Medicare claims. This allowed identiﬁcation of the ﬁrst predialysis vascular
access placed rather than just the ﬁrst access used for hemodialysis. All-
cause mortality outcomes based on the ﬁrst vascular access placed were
evaluated using proportional hazard models. The ﬁstula group was the
reference. In the study population, 21,436 patients had ﬁstulas as the ﬁrst
predialysis access placed, 3472 had grafts as the ﬁrst predialysis access, and
90,517 had catheters as the ﬁrst predialysis access. Patients with catheters
as their ﬁrst predialysis access demonstrated inferior survival compared
with patients with a ﬁstula (hazard ratio [HR], 1.77; 95% conﬁdence
interval [CI], 1.73-1.81; P < .001). There was no signiﬁcant difference
in mortality between patients with a graft as the ﬁrst access placed and
those with a ﬁstula as the initial access (HR, 1.05; 95% CI, 1.00-1.11;
P ¼ .06). Patients with grafts as their ﬁrst predialysis access had inferior
mortality outcomes compared with ﬁstulas for the group aged 67 to
#79 years (HR, 1.10; 95% CI, 1.02-1.17; P ¼ .007). However, differ-
ences between graft-ﬁrst and ﬁstula-ﬁrst groups were not statistically signif-
icant for the groups aged 80 to #89 years those aged >90 years. Overall,
only 50.7% of elderly patients with an AV ﬁstula placed ﬁrst used an AV
ﬁstula at the time of hemodialysis initiation. A higher percentage of those
patients within the AV ﬁstula-ﬁrst group used catheters at dialysis initiation
compared with the AV graft-ﬁrst group (43% vs 25%).
Comment: It is becoming increasingly evident that a ﬁstula-ﬁrst
strategy as a blanket strategy may not be appropriate for all patients
approaching hemodialysis. The authors’ data argue strongly for the fact
that perhaps what is more important is avoiding a catheter in the elderly
patient rather than whether hemodialysis is initiated with a ﬁstula or a graft.
The observational data here suggest placing an AV graft ﬁrst decreases the
chance of initiating hemodialysis with a catheter compared with a ﬁstula-ﬁrst
strategy. The clinical implication is that a ﬁstula-ﬁrst strategy should be used
in elderly patients who have a high chance for a successful ﬁstula but that the
remainder of patients should be considered for a graft to initiate
hemodialysis.Systematic Review and Meta-Analysis of Additional Technologies To
Enhance Angioplasty for Infrainguinal Peripheral Arterial Occlusive
Disease
Simpson EL, Michaels JA, Thomas SM, et al. Br J Surg 2013;100:
1128-37.
Conclusions: Among technologies available to enhance conventional
percutaneous transluminal balloon angioplasty (PTA), self-expanding stents,
drug-eluting stents, and drug-coated balloons appear to be the most prom-
ising technologies for future study.
Summary: There are a number of modiﬁcations of balloon angio-
plasty aimed at improving success of the initial recanalization and prevention
of late restenosis in the percutaneous treatment of infrainguinal peripheral
arterial occlusive disease. These technologies include stents, laser angio-
plasty, arthrectomy devices, drug-eluting stents, drug-coated balloons,
endovascular radiotherapy, and brachytherapy. This review is part of a larger
project looking at enhancements to angioplasty (Simpson EL et al, http://
www.hta.ac.uk/project/2324.asp). The purpose of the review was to eval-
uate the range of available additional technologies to enhance results of
infrainguinal PTA. The authors searched relevant electronic databases in
May 2011. The patient population studied was those with symptomatic
peripheral arterial occlusive disease undergoing endovascular treatment for
disease distal to the inguinal ligament. Interventions were additional tech-
niques compared with conventional PTA. Need for reintervention and
restenosis were the main outcome measures. Randomized clinical trials
were assessed for quality, and data were extracted to determine clinical effec-
tiveness. Where appropriate, meta-analysis was undertaken to produce risk
ratios (RRs). There were 40 randomized clinical trials selected. Meta-anal-
ysis showed a signiﬁcant beneﬁt at 6 months in reducing restenosis for
self-expanding stents (RR, 0.49) and drug-coated balloons (RR, 0.40)
and at 12 months for endovascular brachytherapy (RR, 0.63). Stent grafts
also signiﬁcantly reduced stenosis compared with PTA, as did drug-eluting
stents compared with bare-metal stents. The meta-analysis showed drug-
coated balloons were associated with lower reintervention rates than PTA
alone at 6 months (RR, 0.24) and at 24 months (RR, 0.27). Self-expanding
stents at 6 months also appeared to result in lower reintervention rates.
Other techniques did not show signiﬁcant treatment effects for restenosis
or reintervention.
Comment: It seems that every few months there is a new “wonder
technique” to reduce restenosis and reintervention in patients undergoing
percutaneous treatment of infrainguinal arteries. Although the conclusions
of this review must be tempered by small sample sizes and, frequently, by
lack of clinical outcome measures permitting direct comparison between
trials, it does appear not all adjuncts to balloon angioplasty are equal.
Because there are limited resources available for study of these adjuncts,
the value of this review is to identify those adjuncts most likely to have
beneﬁt when studied with respect to patient-oriented outcomes such as
measures of quality of life, reintervention, and symptomatic recurrence.
Myocardial Injury After Noncardiac Surgery and its Association With
Short-Term Mortality
van Waes JAR, Nathoe HM, de Graaff JC, et al; and the Cardiac Health
After Surgery (CHASE) Investigators. Circulation 2013;127:2264-71.
Conclusions: Postoperative myocardial injury is an independent
predictor of 30-day mortality after noncardiac surgery.
Summary: In high-risk surgical patients, isolated troponin elevations
are strong independent predictors of mortality within the ﬁrst year after
surgery (Levy M et al, Anesthesiology 2001;114:796-806). The VISION
study (Vascular Events in Noncardiac Surgery Patients Cohort Evaluation)
included >15,000 surgical patients and showed a strong association
between peak troponin levels postoperatively and 30-day mortality (Dever-
eaux PJ et al, JAMA 2012;307:2295-304). On the basis of the VISION
study, it has been suggested that routine postoperative troponin monitoring
could be implemented as standard of care in appropriate patients under-
going noncardiac surgery to provide better risk stratiﬁcation and long-
term patient management. The authors therefore sought to determine
the predictive value of postoperative troponin elevation with respect to
30-day mortality after noncardiac surgery. This was an observational
single-center cohort study of 2232 noncardiac surgical patients considered
intermediate-risk to high-risk. Patients were aged $60 years and underwent
surgery in 2011. Troponin was measured for the ﬁrst 3 postoperative days.
The association between postoperative myocardial injury (troponin I level
>0.06 mg/L) and all-cause 30-day mortality was determined using log
binomial regression analysis. Of the 1627 patients in whom troponin was
measured, 315 (19%) had myocardial injury as indicated by an elevated
troponin I level. All-cause death occurred in 56 patients (3%). The relative
risk of a minor increase in troponin (0.07-0.59 mg/L) was 2.4 (95% conﬁ-
dence interval, 1.3-4.2; P < .01). The relative risk of a 10- to 100-fold
